Helen Louise Collins, Chief Medical Officer, on July 17, 2026, sold 5,000 shares in Enliven Therapeutics (ELVN) for $263,373. Following the Form 4 filing with the SEC, Collins has control over a total of 25,000 common shares of the company, with 25,000 shares held directly.
SEC Filing:
Jennifer Tejada, Director, Executive Chair, on July 16, 2026, sold 398,947 shares in Pagerduty (PD) for $4,240,938. Following the Form 4 filing with the SEC, Tejada has control over a total of 1,944,823 common shares of the company, with 1,678,251 shares held directly and 266,572 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1568100/000173697926000013/xslF345X05/wk-form4_1784583262.xml
Hamid Moghadam, Director, on July 16, 2026, sold 50,000 shares in Prologis (PLD) for $7,495,500. Following the Form 4 filing with the SEC, Moghadam has control over a total of 2,026,271 common shares of the company, with 2,026,271 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1045609/000119312526309058/xslF345X05/ownership.xml
Jill Foss Watson, 10% Owner, on July 16, 2026, sold 1,436 shares in Credit Acceptance (CACC) for $919,788. Following the Form 4 filing with the SEC, Watson has control over a total of 47,910 common shares of the company, with 47,910 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/885550/000156898226000004/xslF345X05/primary_doc.xml